In the news
View the latest updates from the 59 North team and our clients below:
03
Nov
2025
AAVantgarde Closes $141 Million Series B for Stargardt Disease and Usher 1B Syndrome clinical development
31
Oct
2025
Rafiq Hasan discusses Complement Tx’s FDA IND clearance to advance CTx001 into Opti-GAIN Phase I/II Trial in GA secondary to AMD on BiotechTV
30
Oct
2025
Anti-CEA affibody for improved cancer detection and imaging
27
Oct
2025
For the first time the blind can see again
27
Oct
2025
ten23 health and Neumirna Therapeutics Team up to Develop RNA Therapy for Epilepsy
26
Oct
2025
SiPore passes the Daily Mail test
25
Oct
2025
Women’s Health high on the agenda at NLSDays
25
Oct
2025
Shahrzad Missaghi from Colorcon previews OSD trends for the Pharma Navigator
24
Oct
2025
Sweden and Switzerland strengthen ties
24
Oct
2025
BioXconomy report from Nordic Life Science Days on the culture driving success
23
Oct
2025
Dicot Announces Positive Results of Phase IIa study for new ED drug, LIB-01
21
Oct
2025
First Patients Enrolled in Diagnostic Phase 2 Imaging Study with Affibody’s PET Imaging Agent Tezatabep Matraxetan in Metastatic Breast Cancer
20
Oct
2025
Science Publishes Paper on PRIMA Vision Restoration Implant in NEJM
17
Oct
2025
Labiotech’s Jules Adam explores what the future holds for Swedish biotech
16
Oct
2025
GlobalData’s Rob Barrie reports on how Sweden is building one of Europe’s most dynamic biotech ecosystems.
15
Oct
2025
BD, ten23 health, and Partners to Demo full RFID Syringe Traceability at CPHI Frankfurt
13
Oct
2025
Cellevate to Announce Major Advances in Yield and Scalability of Viral Vaccine Production at WVC Europe with Global Launch of Cellevat3d® VAX Nanofiber Microcarriers
13
Oct
2025
Chris Spivey of PharmExec.com interviews ten23 Health CEO Hanns-Christan Mahler on understanding and managing risk in fill and finish manufacturing
08
Oct
2025
PharmNovo Secures CTA Approval in Spain initiating Phase IIa Trial of PN6047 to Treat Neuropathic Pain without Risk of Addiction
08
Oct
2025
Shani Alexander hears from AI Medical Technologies CEO Christoffer Ekstrom about how AI is revolutionising skin cancer detection
07
Oct
2025
Affibody Doses First Patient in Phase I Trial of ABY-271 for HER2+ Metastatic Breast Cancer
06
Oct
2025
NanoPhoria Announces Largest Ever Italian Series A Biotech Raise for HF Indication
02
Oct
2025
AAVantgarde Bio receives ODD and CTA for AAVB-039 to address Stargardt Disease
30
Sep
2025
Resitu Medical Receives 510(k) Marketing Authorization from US FDA for its Breast Biopsy Device
22
Sep
2025
Nanexa receives Japanese Patent Approval for Specific PharmaShell Structure
22
Sep
2025
Affibody Reports Positive 16-week Phase 3 Data of Izokibep in Hidradenitis Suppurativa Presented at EADV 2025
15
Sep
2025
Limula Announces Collaboration with Leading Cancer Centre to Improve Blood Products Processing for Stem Cell Transplantation
09
Sep
2025
CEO David Bejker explains how Affibody’s approach can solve many of the challenges facing radioligand therapy on BioBiz Buzz